SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –– Additional data from the Phase 3 DeFi trial of ... Read More

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

"There was a strong signal in the phase III trial suggesting ... of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or ... Read More

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim ... Read More

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Based on the encouraging weight loss, as well as the safety and tolerability results to date ... various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed ... Read More

Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer

Volastra’s two KIF18A inhibitors are in parallel Phase ... Volastra Therapeutics is a New York-based clinical-stage biotechnology company pioneering novel approaches to treating cancer by ... Read More

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Positive results from the trial will provide the basis to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA), and we remain on track with topline data expected from ... Read More

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics ... treatment of cancer, today announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested ... Read More

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR ... results from a Phase 1a trial. This press release contains forward-looking ... Read More

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo. Significant changes in multiple ALS disease pathways support NurOwn's mechanism of ... Read More

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Notes: Safety population, includes all randomized subjects who received at least one dose of study drug or placebo. Based on the encouraging weight loss, as well as the safety and tolerability results ... Read More